Vortioxetine Hydrobromide
You are here: Home » Products » API » Mental Nerves APIS » Vortioxetine Hydrobromide » Vortioxetine Hydrobromide

loading

Vortioxetine Hydrobromide

CAS No.:960203-27-4
Formula:C18H23BrN2S
Type:Pharmaceutical API
Appearance:Powder
Certificate:GMP, COPP, WC, DMF
Shelf Life:2 years
Quality Standard:CP, EP, JP, USP
Assay:98.0%-102.0%
Chemical Name:1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine;hydrobromide
Availability:
Quantity:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button


Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.


Function


Vortioxetine is indicated for the treatment of major depressive disorder (MDD).


Package


1.00kg/bag, 2.00kg/bag, 5.00kg/bag or according to customer’s requirements.



Related News

content is empty!

Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.

QUICK LINKS

PRODUCT CATEGORY

Copyright © 2023 Shandong Loncom Pharmaceutical Co., Ltd. All Rights Reserved. Sitemap | Privacy Policy
Supported by leadong.com
Contact Us